Henry Ford Health

Henry Ford Health Scholarly Commons
Urology Articles

Urology

1-1-2016

Evaluation of a genomic classifier in radical prostatectomy
patients with lymph node metastasis.
Hak J. Lee
Kasra Yousefi
Zaid Haddad
Firas Abdollah
Henry Ford Health, FABDOLL1@hfhs.org

Lucia L. Lam

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/urology_articles

Recommended Citation
Lee HJ, Yousefi K, Haddad Z, Abdollah F, Lam LL, Shin H, Alshalalfa M, Godebu E, Wang S, Shabaik A,
Davicioni E, and Kane CJ. Evaluation of a genomic classifier in radical prostatectomy patients with lymph
node metastasis. Res Rep Urol 2016; 8:77-84.

This Article is brought to you for free and open access by the Urology at Henry Ford Health Scholarly Commons. It
has been accepted for inclusion in Urology Articles by an authorized administrator of Henry Ford Health Scholarly
Commons.

Authors
Hak J. Lee, Kasra Yousefi, Zaid Haddad, Firas Abdollah, Lucia L. Lam, Heesun Shin, Mohammed
Alshalalfa, Elana Godebu, Song Wang, Ahmed Shabaik, Elai Davicioni, and Christopher J. Kane

This article is available at Henry Ford Health Scholarly Commons: https://scholarlycommons.henryford.com/
urology_articles/120

Research and Reports in Urology

Dovepress
open access to scientific and medical research

O rigi n al R esearch

Open Access Full Text Article

Evaluation of a genomic classifier in radical
prostatectomy patients with lymph node
metastasis
This article was published in the following Dove Press journal:
Research and Reports in Urology
28 June 2016
Number of times this article has been viewed

Hak J Lee 1
Kasra Yousefi 2
Zaid Haddad 2
Firas Abdollah 3
Lucia LC Lam 2
Heesun Shin 2
Mohammed Alshalalfa 2
Elana Godebu 1
Song Wang 4
Ahmed Shabaik 5
Elai Davicioni 2
Christopher J Kane 1
Department of Urology, University
of California, San Diego, San Diego,
CA, USA; 2GenomeDx Biosciences
Inc., Vancouver, BC, Canada; 3Vattikuti
Urology Institute, Henry Ford
Hospital, Detroit, MI, 4UC San Diego
Health System, San Diego, CA,
5
Department of Pathology, University
of California, San Diego, San Diego,
CA, USA
1

Objective: To evaluate the performance of the Decipher test in predicting lymph node invasion
(LNI) on radical prostatectomy (RP) specimens.
Methods: We identified 1,987 consecutive patients with RP who received the Decipher test
between February and August 2015 (contemporary cohort). In the contemporary cohort, only
the Decipher score from RP specimens was available for analysis. In addition, we identified
a consecutive cohort of patients treated with RP between 2006 and 2012 at the University of
California, San Diego, with LNI upon pathologic examination (retrospective cohort). The
retrospective cohort yielded seven, 22, and 18 tissue specimens from prostate biopsy, RP, and
lymph nodes (LNs) for individual patients, respectively. Univariable and multivariable logistic
regression analyses were used to evaluate the performance of Decipher in the contemporary
cohort with LNI as the endpoint. In the retrospective cohort, concordance of risk groups was
assessed using validated cut-points for low (,0.45), intermediate (0.45–0.60), and high (.0.60)
Decipher scores.
Results: In the contemporary cohort, 51 (2.6%) patients had LNI. Decipher had an odds ratio
of 1.73 (95% confidence interval, 1.46–2.05) and 1.42 (95% confidence interval, 1.19–1.7) per
10% increase in score on univariable and multivariable (adjusting for pathologic Gleason score,
extraprostatic extension, and seminal vesicle invasion), respectively. No significant difference in
the clinical and pathologic characteristics between the LN positive patients of contemporary and
retrospective cohorts was observed (all P.0.05). Accordingly, among LN-positive patients in the
contemporary cohort and retrospective cohort, 80% and 77% had Decipher high risk scores (P=1).
In the retrospective cohort, prostate biopsy cores with the highest Gleason grade and percentage
of tumor involvement had 86% Decipher risk concordance with both RP and LN specimens.
Conclusion: Decipher scores were highly concordant between pre- and post-surgical specimens.
Further, Decipher scores from RP tissue were predictive of LNI at RP. If validated in a larger
cohort of prostate biopsy specimens for prediction of adverse pathology at RP, Decipher may
be useful for improved pre-operative staging.
Keywords: prostate, biopsy, lymph node invasion, genomic classifier, radical prostatectomy,
decipher, prognosis

Introduction
Correspondence: Christopher J Kane
Department of Urology, University
of California, San Diego, 3855 Health
Sciences Drive, MC0987, La Jolla CA
92093-0987 San Diego, CA, USA

Recently, development of genomic signatures in prostate cancer has improved our
understanding of disease biology.1,2 Decipher® represents one such test that was developed
to predict disease progression after radical prostatectomy (RP) in a cohort of 359 patients.3
Since its conception, Decipher has been validated in multiple cohorts with varying
levels of risk and patient populations.4–13 In a majority of previous studies, Decipher was
performed using formalin-fixed paraffin embedded specimens from whole gland pathol77
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ogy.4–13 Only recently, performance and feasibility of Decipher
on prostate biopsy (PBx) specimens have been studied.10 In
the present study, we set to: 1) determine the agreement of
Decipher among matched PBx, RP, and lymph node (LN)
pathologic specimens from individual patients and 2) evaluate
the performance of the Decipher genomic classifier in predicting lymph node invasion (LNI) on RP specimens.

Materials and methods
Patient cohorts
We identified 1,987 consecutive patients with RP who
received the Decipher test between February 1 and August
1, 2015, from 308 centers. This contemporary cohort was
deidentified, and study researchers were blinded to patient
identities and had no access to personally identifiable health
information (ClinicalTrials.gov number, NCT02609269).
The Qurorum Institutional Review Board (record number:
31079) approved the research protocol for this study. Since
all patient related data was de-identified and study researchers were blinded to patient identities and did not have access
to personally identifiable health information, it was exempt
from human subjects review, and members of the study
population did not have to provide informed consent. In
the contemporary cohort, only the Decipher score from RP
specimens was available for analysis.
The retrospective cohort consisted of 25 consecutive
patients treated with RP between 2006 and 2012 with pathologically determined LN metastases (LNI) and available tissue
blocks and clinical data at the University of California, San
Diego. For each patient, three PBx cores from their diagnostic
PBx with tumor tissue were selected based on availability of
sufficient tissue for genomic analysis. Likewise, RP and LN
specimens positive for tumor were retrieved. For 16 patients,
a matched diagnostic PBx core specimen was not available.
After filtering for specimens that failed microarray quality
control, retrospective cohort yielded seven, 22, and 18 tissue
specimens from PBx, RP, and LNs for individual patients,
respectively. All specimens were rereviewed by an expert
uropathologist (A.S). The index tumor was considered as the
lesion with the highest Gleason score sampled using a 1.5
mm punch tool. The “index” PBx was defined as the core
with the highest Gleason score and highest percentage of
tumor involvement. The University of California, San Diego,
institutional review board approved the research protocol
under which this study was conducted.

Calculation of Decipher
The expression values for the 22 prespecified biomarkers that
constitute Decipher were extracted from the normalized data
78

submit your manuscript | www.dovepress.com

Dovepress

matrix and entered into the locked random forest algorithm
with tuning and weighting parameters defined previously.3
The Decipher readout is a continuous risk score between
0 and 1, with higher scores indicating a greater probability
of disease progression or metastasis.3,7,10 Decipher was also
stratified into low (,0.45), intermediate (0.45–0.60), and
high (.0.60) risk groups based on previously developed and
validated cut-points.9,14

Statistical analysis
Univariable and multivariable (MVA) logistic regression
analyses were used to evaluate the performance of Decipher
in predicting LNI in the contemporary cohort. The c-index
of the pathologic and Decipher plus pathologic models was
estimated by subjecting the model to bootstrapping with
10,000 resamples. Fisher’s exact test was used to study the
association of clinicopathologic variables between study
cohorts. Exact binomial confidence intervals (CIs) were
constructed to measure the concordance of Decipher score
among matched PBx, RP, and LN pathologic specimens in
the retrospective cohort. Pairwise agreement of Decipher
scores in the retrospective cohort was evaluated using Bland–
Altman plots.15 All statistical tests involving biopsy samples
were performed after index PBx sample selection unless
stated otherwise. In the retrospective cohort, Kaplan–Meier
method was used to estimate two endpoints: 1) biochemical recurrence rate, which was defined as a postoperative
prostate-specific antigen (PSA) value .0.2 on two consecutive measurements; and 2) clinical recurrence rate, which
was defined as local, and/or distant recurrence defined by
imaging, and/or prostate-bed biopsy. Statistical analyses
were performed using the R statistical software (R Foundation for Statistical Computing, Vienna, Austria) considering
a statistical significance at P,0.05.

Results
Patient characteristics
The clinical and pathologic characteristics of patients tested
with Decipher in the contemporary cohort are summarized
in Table 1. Median age at surgery was 67 years (interquartile range [IQR], 61–71). Median pre-operative PSA
was 6.4 ng/mL (IQR: 4.7–9.6). Overall, 75.5%, 11.1%, and
13.3% of patients had pathologic Gleason score #7, 8, and
$9, respectively; 58.9% of patients harbored pT3 disease;
and 55.4% had positive surgical margins. Fifty-one (2.6%)
patients presented with LNI at RP.
In the retrospective cohort, 22 patients had complete clinical and pathologic characteristics and Decipher RP scores for
analysis. A subset of 7 and 18 patients had tissue available
Research and Reports in Urology 2016:8
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Table 1 Patient clinical and pathologic characteristics in the
contemporary cohort

Table 2 Patient clinical and pathologic characteristics in the
retrospective cohort

Variables

Total (%)

Variables

Total (%)

No patients (%)
Age, year, median (IQR)
Pre-operative PSA (ng/mL), median (IQR)
Pathologic Gleason score, n (%)
#7
8
$9
Unknown
Pathologic stage, n (%)
T2
T3a
T3b
T4
Unknown
Positive surgical margins, n (%)
Lymph node invasion, n (%)

1,987 (100)
65 (62–69)
6.4 (4.7–9.6)

No patients (%)
Age, year, median (IQR)
Pre-operative PSA (ng/mL), median (IQR)
Pathologic Gleason score, n (%)
#7
8
$9
Unknown
Pathologic stage, n (%)
T2
T3a
T3b
T4
Positive surgical margins, n (%)
Lymph node invasion, n (%)
Follow-up time (censored), mo, median (IQR)

22 (100)
60 (57–66)
6.9 (4.8–16.1)

1,500 (75.5)
220 (11.1)
264 (13.3)
3 (0.2)
772 (38.9)
780 (39.3)
390 (19.6)
14 (0.7)
31 (1.6)
1,100 (55.4)
51 (2.6)

2 (9.1)
9 (40.9)
11 (50.0)
0 (0)
3 (13.6)
8 (36.4)
10 (45.5)
1 (4.5)
12 (54.5)
22 (100)
16 (4–35)

Abbreviations: IQR, interquartile range; PSA, prostate-specific antigen.

Abbreviations: IQR, interquartile range; mo, months; PSA, prostate-specific antigen;
yr, year.

from PBx and LN specimens, respectively. Retrospective
cohort patients’ clinical and pathologic characteristics are
summarized in Table 2. Median age at surgery was 60
years (IQR, 57–66). Median pre-operative PSA value was
6.9 ng/mL (IQR, 4.8–16.1). At biopsy, 91% had Gleason
score 8–10, 41% had clinical stage T2b disease, and 90.9%
were classified as high risk by National Comprehensive

Cancer Network (NCCN) criteria. At RP, 90.9% of patients
had Gleason score 8–10, 81.9% harbored pT3 disease, and
54.5% had positive surgical margins. The median follow-up
time for this cohort was 16 months (IQR, 4–35). At 5 years
post-RP, the estimated biochemical recurrence rate and
clinical recurrence rate were 73% and 24%, respectively
(Figure S1). A comparison of the clinical and pathologic

100

n=824
(41.5%)

Frequency (%)

75

n=41
(80.4%)

n=17
(77.3%)

n=5
(9.8%)
n=5
(9.8%)

n=3
(13.6%)

Contemporary cohort
LN+ patients
N=51

Retrospective cohort
LN+ patients
N=22

n=423
(21.3%)

50

25

n=740
(37.2%)

0
Contemporary cohort
all patients
N=1,987
Decipher risk

Low (<0.45)

n=2
(9.1%)

Intermediate (0.45–0.60)

High (>0.6)

Figure 1 Bar charts showing frequency of Decipher risk groups in (left) contemporary cohort, (center) LN+ patients of contemporary cohort, and (right) LN+ patients of
retrospective cohort from genomic marker assessment in RP specimens.
Abbreviations: LN, lymph node; RP, radical prostatectomy.
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characteristics of the LNI patients in the contemporary and
retrospective cohorts did not show any significant difference
(all P.0.1) between the two cohorts (Table S1).
Patients were also stratified using Decipher risk groups
(low, intermediate, and high). In the contemporary cohort,
9.8%, 9.8%, and 80.4% of LN positive patients were categorized as Decipher low, intermediate, and high risk, respectively
(Figure 1). In the retrospective cohort, we observed a similar
distribution with 9.1%, 13.6%, and 77.3% categorized into
Decipher low, intermediate, and high risk, respectively. There
was no significant difference with respect to Decipher distribution of LN positive patients between the two cohorts (P.0.1).

Evaluation of Decipher for LNI prediction
in the contemporary cohort
On univariable, Decipher had an odds ratio (OR) of 1.73
(95% CI, 1.46–2.05, P,0.001) per 10% increase in score
for predicting the presence of LNI (Table 3). Gleason score

Table 3 Univariable logistic regression analysis of Decipher and
pathologic variables for prediction of lymph node invasion in the
contemporary cohort
Variables/endpoint
Deciphera
Pathologic Gleason score 3+3
Pathologic Gleason score 3+4
Pathologic Gleason score 4+3
Pathologic Gleason score 8
Pathologic Gleason score $9
Extraprostatic extension
Seminal vesicle invasion

OR (95% CI)

P-value

1.73 (1.46–2.05)
ref
0.78 (0.08–7.58)
2 (0.24–16.78)
8.77 (1.18–65.29)
6.01 (0.79–45.89)
6.1 (2.59–14.35)
5.74 (3.25–10.13)

,0.001
1
0.83
0.52
0.03
0.08

8 disease had an OR of 8.77 (95% CI, 1.18–65.29, P=0.03).
Extraprostatic extension (EPE) and seminal vesicle invasion (SVI) also were significant predictors of LNI with OR
TP 75%, GG 5

TP 50%, GG 4

8

TP 80%, GG 5

TP 100%, GG 5

23

TP 90%, GG 4

TP 100%, GG 4

TP 80%, GG 4

TP 100%, GG 4

1
TP 80%, GG 3

TP 60%, GG 4

TP 80%, GG 4

TP 100%, GG 4 TP 90%, GG 4
TP 95%, GG 4

TP 5%, GG 4

TP 95%, GG 5

TP 100%, GG 5

13

TP 80%, GG 4

TP 60%, GG 4

16

TP 60%, GG 4

TP 90%, GG 4

24
10

TP 50%, GG 5

21

TP 10%, GG 4

6

TP 50%, GG 4

TP 90%, GG 4

TP 50%, GG 5

TP 80%, GG 4

TP 90%, GG 4

TP 100%, GG 4 TP 50%, GG 4
TP 100%, GG 4 TP 100%, GG 4

22

TP 85%, GG 4

17

TP 50%, GG 4

TP 20%, GG 4

TP 30%, GG 4

TP 90%, GG 4

TP 50%, GG 4

TP 100%, GG 4

2

TP 75%, GG 4

TP 100%, GG 4

TP 75%, GG 5

7
5

TP 90%, GG 5

TP 100%, GG 5 TP 75%, GG 5

20

TP 70%, GG 5

3

TP 90%, GG 5

TP 100%, GG 5

TP 50%, GG 3

TP 50%, GG 3

14

TP 60%, GG 3

TP 60%, GG 3

TP 50%, GG 4

19

TP 100%, GG 4

26

TP 90%, GG 3

4

TP 100%, GG 5
PBx1

,0.001
,0.001

Note: aDecipher reported per 0.1 unit increase. A statistical significance at P,0.05
was applied.
Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference group.

9

18

Patient ID

Lymph node invasion

PBx2

PBx3

TP 5%, GG 3

RP

LN

Tumor type
Decipher risk

Low (<0.45)

Intermediate (0.45–0.60)

High (>0.60)

Unknown

Figure 2 Heat map of Decipher risk groups for all patients in the retrospective cohort.
Abbreviations: GG, highest Gleason grade; LN, lymph node; PBx, prostate biopsy; RP, radical prostatectomy; TP, tumor percentage.
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Table 4 Multivariable logistic regression analysis of Decipher and
pathologic variables for prediction of lymph node invasion in the
contemporary cohort
Variables/endpoint
Deciphera
Pathologic Gleason score 3+3
Pathologic Gleason score 3+4
Pathologic Gleason score 4+3
Pathologic Gleason score 8
Pathologic Gleason score $9
Extraprostatic extension
Seminal vesicle invasion

Lymph node invasion
OR (95% CI)

P-value

1.42 (1.19–1.7)
ref
0.39 (0.04–3.92)
0.56 (0.06–4.95)
1.84 (0.23–14.73)
0.85 (0.1–7.09)
3.48 (1.44–8.41)
2.73 (1.47–5.08)

,0.001
1
0.43
0.6
0.57
0.88
0.01
,0.001

Note: aDecipher reported per 0.1 unit increase. A statistical significance at P,0.05
was applied.
Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference group.

of 6.10 (95% CI, 2.59–14.35, P,0.001) and 5.74 (95% CI,
3.25–10.13, P,0.001), respectively. Patient age at RP and
pre-operative PSA were not significant predictors of LNI
(data not shown). Patient age at RP and pre-operative PSA
were not modeled on MVA as these variables were missing
for a significant portion of patients.
On MVA, adjusting for pathologic Gleason score, EPE,
and SVI Decipher had an OR of 1.42 (95% CI, 1.19–1.7,
P,0.001) per 10% increase in score for predicting the
presence of LNI (Table 4). EPE and SVI also remained
significant predictors of LNI on MVA. In contrast, Gleason
score 8 disease did not remain significant for predicting LNI
after adjusting for Decipher and other pathologic variables.
Similar results were observed in univariable and MVA for
Decipher risk groups (Tables S2 and S3). On MVA analysis
adjusting for pathologic Gleason score, EPE, and SVI, the
Decipher high risk group (.0.6) had an OR of 3.23 (95%
CI, 1.2–8.73, P=0.02), similar to the OR of EPE and SVI
for predicting the presence of LNI. Finally, discrimination
analysis showed that Decipher had a c-index of 0.78 (95%
CI, 0.71–0.84) for prediction of LNI. Combination of
Decipher with pathologic variables increased the c-index to
0.85 (95% CI, 0.73–0.86) from 0.83 (95% CI, 0.71–0.84)
for pathologic model alone (Figure S2).

Concordance of Decipher in pre- and
post-RP tissue specimens in the
retrospective cohort
A patient-per-patient pairwise agreement among biopsy cores
(#3 cores for each patient with available Decipher scores),
RP, and LN specimens is shown in Figure 2. Among all available PBx specimens, 65% were categorized as Decipher high
risk, whereas 100% of selected PBx specimens (highest sampled Gleason grade and percentage of tumor involvement),
Research and Reports in Urology 2016:8

77% RP, and 78% LN specimens had high Decipher scores.
Bland–Altman plots, which examined patient-per-patient
agreement, showed a good overall concordance for all three
compared tissue specimens (Figure S3).
Finally, we examined Decipher agreement in pairwise
comparisons between the following 1) PBx and RP specimens, 2) PBx and LN specimens, and 3) RP and LN specimens when PBx selection was performed (Table 5). Without
selection of PBx specimens (ie, taking the average Decipher
score for all cores), the overall concordance with RP Decipher
risk groups was 71%, which increased to 86% concordance
when the selected PBx core (ie, with the highest sampled
Gleason grade and percentage of tumor involvement) was
compared to RP Decipher. The concordance between PBx
and LN was 43% for the average of all PBx specimens in
each patient and similarly increased to 86% when comparing only the PBx with highest sampled Gleason grade and
percentage of tumor involvement. The concordance of RP
and LN Decipher scores was 72%.

Discussion
Here, we evaluated the performance of Decipher scores on
RP specimens for prediction of LNI in a contemporary cohort
and then in an exploratory analysis of a small retrospective
cohort determined the agreement of Decipher scores among
pre- and post-operative tissue specimens, including LN with
tumor involvement. Our results show that Decipher is a strong
predictor of LNI in a contemporary cohort of nearly 2,000
patients. In a retrospective cohort, with similar characteristics
to the LNI patients of a contemporary RP cohort, we observed
high concordance between Decipher scores in PBx and both
RP and LN specimens of individual patients. The caveat is that
this is only true when the PBx sampled with highest Gleason
grade and percentage of tumor involvement is selected.
Our study has several limitations. In the contemporary
cohort: the lack of information on pre-operative variables,
extended pelvic lymph node dissection (ePLND) status, and
Table 5 Concordance of Decipher scores across tumor types
using various selection methods for biopsy samples with multiple
tumors in the retrospective cohort
Pairwise
comparison

Overall
concordance

Concordance/PBx
selected based on highest
TP and dominant GG

PBx-RP (%)
PBx-LN (%)
RP-LN (%)

71 (29–96)a
43 (10–82)a
72 (47–90)

86 (42–100)
86 (42–100)
72 (47–90)

Note: aIn case of a tie, sample with highest tumor percent and dominant Gleason
grade was selected.
Abbreviations: GG, highest Gleason grade; LN, lymph node; PBx, prostate biopsy;
RP, radical prostatectomy; TP, tumor percentage.
submit your manuscript | www.dovepress.com
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number of LN retrieved for all patients. In the retrospective
cohort: the small sample size of the matched PBx specimens
and the lack of a matched set of control patients (ie, without
LNI) to determine the discrimination performance of the
genomic marker expression in PBx for predicting LNI. We
aimed to address these issues in part by considering a large
contemporary cohort that included both LN negative and
positive patients in order to show the discrimination of the
genomic marker for predicting the presence of LNI. However,
further validation of Decipher on larger PBx cohorts is warranted to confirm the results of the current study.

Conclusion
In summary, in our study, Decipher was highly predictive of LNI
from analysis of RP specimens in a large contemporary cohort.
Improved post-operative LNI staging may be useful for selection
of patients for adjuvant hormonal or whole pelvic irradiation.
Decipher scores were also highly concordant between pre- and
post-operative specimens. If validated in a larger cohort of PBx
specimens, Decipher may improve pre-operative staging, which
is useful for optimal selection of patients for neoadjuvant therapy,
primary radiotherapy as well as RP with ePLND.
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Supplementary materials
Table S1 Comparison of LNI patient characteristics from
retrospective and contemporary cohorts
Variables

Retrospective Contemporary P-value*
cohort N=22 cohort LN
N=51

Patient characteristics
Age, yr, median (IQR)
60 (57–66)
Pre-operative PSA
6.9 (4.8–16.1)
(ng/mL), median (IQR)
Pathologic Gleason
score, n (%)
2 (9.1)
#7
8
9 (40.9)
11 (50.0)
$9
Unknown
0 (0.0)
Pathologic stage, n (%)
T2
3 (13.6)
T3a
8 (36.4)
T3b
10 (45.5)
T4
1 (4.5)

65 (64–68)
7.58 (5.1–11.8)
.0.1
10 (19.6)
25 (49.0)
15 (29.4)
1 (2.0)

Table S3 Multivariable logistic regression analysis of categorical
Decipher and pathologic variables for prediction of lymph node
invasion in the contemporary cohort
Variables/endpoint
Decipher low risk
Decipher intermediate risk
Decipher high risk
Pathologic Gleason score 3+3
Pathologic Gleason score 3+4
Pathologic Gleason score 4+3
Pathologic Gleason score 8
Pathologic Gleason score $9
Extraprostatic extension
Seminal vesicle invasion

Lymph node invasion
OR (95% CI)

P-value

ref
1.23 (0.35–4.38)
3.23 (1.2–8.73)
ref
0.41 (0.04–4.12)
0.64 (0.07–5.72)
2.46 (0.31–19.57)
1.1 (0.13–9.25)
3.93 (1.63–9.46)
3.09 (1.67–5.73)

1
0.75
0.02
1
0.45
0.69
0.4
0.93
,0.001
,0.001

Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference group.
Note: A statistical significance at P,0.05 was applied.

.0.1
5 (9.8)
16 (31.4)
29 (56.9)
1 (2.0)

Note: *Fisher’s exact test. A statistical significance at P,0.05 was applied.
Abbreviations: IQR, interquartile range; LN, lymph node; LNI, lymph node invasion;
PSA, prostate-specific antigen; yr, year.

Table S2 Univariable logistic regression analysis of categorical
Decipher and pathologic variables for prediction of lymph node
invasion in the contemporary cohort
Variables/endpoint
Decipher low risk
Decipher intermediate risk
Decipher high risk
Pathologic Gleason score 3+3
Pathologic Gleason score 3+4
Pathologic Gleason score 4+3
Pathologic Gleason score 8
Pathologic Gleason score $9
Extraprostatic extension
Seminal vesicle invasion

Lymph node invasion
OR (95% CI)

P-value

ref
1.76 (0.51–6.11)
7.7 (3.03–19.58)
ref
0.78 (0.08–7.58)
2 (0.24–16.78)
8.77 (1.18–65.29)
6.01 (0.79–45.89)
6.1 (2.59–14.35)
5.74 (3.25–10.13)

1
0.37
,0.001
1
0.83
0.52
0.03
0.08
,0.001
,0.001

Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference group.
Note: A statistical significance at P,0.05 was applied.
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Figure S1 Kaplan–Meier estimates of survival-free (A) BCR and (B) CR in retrospective cohort.
Abbreviations: BCR, biochemical recurrence; CR, clinical recurrence; RP, radical prostatectomy.
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Figure S2 ROC curves of Decipher and pathologic variables in the contemporary
cohort.
Abbreviation: CI, confidence interval.
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Figure S3 Pairwise Bland–Altman plots to evaluate agreement of Decipher scores
between (A) PBx and RP, (B) PBx and LNs, and (C) RP and LNs in retrospective
cohort.
Abbreviations: PBx, prostate biopsy; RP, radical prostatectomy; LN, lymph node.
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